The firm is a European venture capital firm that invests in innovative healthcare and health technology companies addressing large global markets. Operating through a distributed team across multiple European countries, the firm primarily invests in European businesses. The firm typically participates in Seed and Series A financings and can invest up to approximately €5M per company over the life of an investment, including follow-on capital. The firm focuses on companies that have already demonstrated early commercial validation through initial revenues, customer adoption, or market traction. The firm takes an active role in helping portfolio companies scale internationally and build sustainable healthcare businesses.  

The firm focuses on healthcare and health technology companies with scalable business models and global market potential. While historically active across therapeutics, medical devices, diagnostics, and digital health, the firm now places greater emphasis on healthtech and B2B healthcare solutions. Key areas of interest include brain health, mental health, women’s health, digital therapeutics, healthcare software, diagnostics, patient engagement platforms, and technologies that improve the efficiency, accessibility, and delivery of healthcare. The firm generally favors companies with commercialized products, established customer demand, and clear pathways to scalable revenue growth.  

From a company and management team perspective, the firm seeks ambitious founders developing differentiated solutions to significant healthcare challenges. While the firm does not maintain strict requirements regarding management team composition or prior entrepreneurial experience, it places significant value on execution capability, market understanding, and international scaling potential. The firm works closely with portfolio companies following investment, providing strategic guidance, industry expertise, and access to a network of operators, investors, and commercial partners. The firm may act as either a lead investor or syndicate participant depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a Europe-based venture capital firm with a dedicated investment strategy focused on diabetes and related disease areas. The firm primarily invests in Seed through Series A companies, with typical investments ranging from approximately €1-3M. The firm evaluates opportunities globally and is open to both leading and co-investing. Backed by a team with deep scientific expertise and extensive industry experience within the diabetes ecosystem, the firm takes an active role in supporting portfolio companies and frequently participates through board and observer positions.  

The firm focuses on diabetes and closely related indications, including comorbidities and complications where diabetes is a primary driver, such as kidney disease, wound care, vision loss, and other metabolic health challenges. The firm invests primarily in medical devices and digital health solutions, with a focus on both hardware and software technologies. Traditional biotechnology therapeutics fall outside the firm’s investment scope. For medical devices, the firm seeks opportunities that have progressed beyond the prototype stage and generated early validation data through laboratory studies, clinical evaluations, or first-in-human testing. For software and digital health solutions, the firm favors products demonstrating commercial traction or clear scalability. Strategic partnerships or demonstrated interest from healthcare providers, hospital systems, or established medical technology companies are viewed favorably, particularly for enterprise-focused solutions.  

From a company and management team perspective, the firm does not maintain specific requirements regarding founder or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital investor headquartered in Asia is an investment arm of a large drug development organization. The firm invests globally across all stages, from Seed through later-stage financings. In addition to providing capital, the firm offers strategic and operational support spanning drug development, regulatory planning, partnering, and commercialization. The firm leverages the broader capabilities and infrastructure of its affiliated organization to help portfolio companies accelerate growth and value creation.  
 
The firm focuses on pharmaceuticals, biotechnology, and medical devices, with a strong emphasis on drug discovery and translational innovation. The firm seeks differentiated therapeutic and medical technology opportunities with strong scientific foundations and commercial potential. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across a broad range of disease areas and development stages, from discovery through clinical development. The firm also participates in licensing, incubation, and strategic business development activities designed to advance promising healthcare technologies.  
 
From a company and management team perspective, the firm seeks founders and leadership teams with strong scientific expertise, differentiated intellectual property, and credible development strategies. The firm prioritizes opportunities supported by high-quality translational science and works closely with management teams to provide development resources, business development support, partnering opportunities, and commercialization expertise. Through its strategic network and operational capabilities, the firm helps portfolio companies accelerate development timelines and expand global market access. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A capital and private equity investor with a flexible investment mandate invests across a wide range of stages and sectors. On the venture capital side, the firm typically participates in Seed through Series B financings and is open to both leading and co-investing. Investments are generally made through special purpose vehicles, with typical allocation sizes ranging from approximately $2M to $20M. The firm primarily focuses on opportunities within the United States.  

Within healthcare and life sciences, the firm invests in therapeutics, medical devices, digital health, and diagnostics. For therapeutics, the firm prefers opportunities that are approaching clinical development or already in clinical trials. Within medical devices, the firm focuses on technologies that are nearing regulatory approval or have already obtained clearance or approval. The firm is disease-agnostic and evaluates opportunities based on the strength of the technology, clinical potential, and commercial opportunity.  

From a company and management team perspective, the firm generally prefers board representation and seeks to work closely with portfolio companies to support strategic growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.